Scivanta Cardiac Monitoring System measures heart performance more accurately: Scivanta Medical

Scivanta Cardiac Monitoring System (SCMS) can accurately measure cardiac performance, according to Scivanta Medical Corporation.

Clinical studies performed at Kaleida Health/Millard Fillmore Hospital in Buffalo, New York have established that Scivanta Cardiac Monitoring System is safe as well, Scivanta Medical said in a press release.

The clinical trial was designed to obtain data concerning the safety and efficacy of the Scivanta Cardiac Monitoring System by comparing mean left atrial pressure measurements obtained from the SCMS to left ventricular end-diastolic pressure readings measured in a simultaneous left heart catheterization procedure performed by a cardiologist in the cardiac catheterization unit.

These measurements of cardiac performance are used by physicians in the critical evaluation of a patient’s cardiac health.

Initial clinical trial showed that  the mean left atrial pressure for five patients, as determined by the SCMS, matched the left ventricular end-diastolic pressure, as determined by the left heart catheterization procedure, within 0.1mmHg to 0.5mmHg.

This translates into a maximum deviation of 3.3% for the SCMS data when compared to the left heart catheterization data.

These results for Scivanta Cardiac Monitoring System are considered by Scivanta to be highly accurate.  There were no adverse events reported during the course of the initial clinical trial.

“Scivanta has conducted an initial clinical trial using a new technique to gather sophisticated, difficult to obtain cardiac hemodynamic information.  If the planned subsequent studies confirm the reliability of this technique, physicians will have readily available information that will surely impact positively on the treatment of numerous cardiac and non cardiac patients,” stated Richard Berger, M.D., a professor of clinical cardiology at the University of Miami Miller School of Medicine and a fellow of the American College of Cardiology.

This information will be attainable with minimal risk due to the Scivanta Cardiac Monitoring System ‘s relatively non invasive technique.

The Scivanta Cardiac Monitoring System is expected to provide the primary measurements of cardiac performance in a minimally invasive and cost-effective manner and is designed to be used outside of an intensive care setting.

Scivanta Medical Corporation is focused on acquiring and developing medical technologies and products.

Scivanta’s first product, the Scivanta Cardiac Monitoring System, formerly known as the Hickey Cardiac Monitoring System, is an innovative cardiac monitoring system that utilizes a two-balloon esophageal catheter to monitor cardiac performance.